Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Siberian Journal of OncologyOpen Access

miR-17-92 and miR-203A clusters as predictors of the clinical course of chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

MPM. L. PerepechaevaОГО. Б. ГореваALA. S. Lyamkina

Discussion

Loading...

Member takes

Overview

Observational analysis reveals specific microRNAs associated with treatment responses in chronic myeloid leukemia, indicating potential theranostic applications.

Key Points

  • Higher expression of miR-17, miR-18a, and miR-20a in acceleration phase CML patients indicates disease progression.
  • Increased levels of miR-19a and miR-19b correlate with favorable prognoses in chronic phase patients compared to blast crisis.
  • Expression of miR-203 in extracellular vesicles correlates with better treatment outcomes, highlighting its significance as a biomarker.
  • MicroRNAs in lymphocytes and plasma show promise as tools for predicting treatment responses and tailoring therapies for CML patients.

Cite This Study

Perepechaeva et al. (2025) studied this question.

synapsesocial.com/papers/68de68e583cbc991d0a20fdbhttps://doi.org/10.21294/1814-4861-2025-24-4-66-81
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, Ethiopia2025 · 1 citations
  2. 2Expression patterns of microRNAs associated with CML phases and their disease related targets2011 · 142 citations
  3. 3The Screening of microRNAs in Chronic Myeloid Leukemia: A Clinical Evaluation2024 · 2 citations
  4. 4miR-155 and miR-223 as markers of biological and clinical features of chronic lymphocytic leukemia2024
  5. 5MicroRNA: A Signature for the Clinical Progression of Chronic Lymphocytic Leukemia2024